The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Open accessAbstract
The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy (Podlaha et al., 2012; Landau et al., 2013) or treated with specific inhibitors (Ding et al., 2012) to those observed here.”
From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Ding et al., 2012
In the citing paper
“For example, the clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy 9.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationTumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citationWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citationCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489
Cited by
Sorted by citations
Items 601–700 of 999
Antibody therapy for acute myeloid leukaemia
Gasiorowski, R., Clark, G. J., Bradstock, K. F., & Hart, D. N. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12691 · Cited by 48
The biology and clinical impact of genetic lesions in myeloid malignancies
Lindsley, R. C., & Ebert, B. L. (2013) · Blood · doi:10.1182/blood-2013-06-460295 · Cited by 50
Werner, B., Dingli, D., & Traulsen, A. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.0349 · Cited by 49
SomVarIUS: somatic variant identification from unpaired tissue samples
Smith, K. S., Yadav, V. K., Pei, S., Pollyea, D. A., Jordan, C. T., & De, S. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv685 · Cited by 49
Kasai, F., Hirayama, N., Ozawa, M., Iemura, M., & Kohara, A. (2016) · Genomics · doi:10.1016/j.ygeno.2016.04.003 · Cited by 49
E-scape: interactive visualization of single-cell phylogenetics and cancer evolution
Smith, M. A., Nielsen, C. B., Chan, F. C., McPherson, A., Roth, A. J. L., Farahani, H., Machev, D., Steif, A., & Shah, S. P. (2017) · Nature Methods · doi:10.1038/nmeth.4303 · Cited by 44
The leukemia strikes back: a review of pathogenesis and treatment of secondary AML
Cheung, E., Perissinotti, A. J., Bixby, D. L., Burke, P. W., Pettit, K. M., Benitez, L. L., Brown, J. M., Scappaticci, G. B., & Marini, B. L. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03606-0 · Cited by 50
An enhanced genetic model of colorectal cancer progression history
Yang, L., Wang, S., Lee, J. J.-K., Lee, S., Lee, E., Shinbrot, E., Wheeler, D. A., Kucherlapati, R., & Park, P. J. (2019) · Genome biology · doi:10.1186/s13059-019-1782-4 · Cited by 48
Stengel, A., Shahswar, R., Haferlach, T., Walter, W., Hütter, S., Meggendorfer, M., Kern, W., & Haferlach, C. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003007 · Cited by 50
Sequencing-based measurable residual disease testing in acute myeloid leukemia
Yoest, J. M., Shirai, C. L., & Duncavage, E. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00249 · Cited by 48
Heuckmann, J. M., & Thomas, R. K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv184 · Cited by 48
Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples
Holley, T., Lenkiewicz, E., Evers, L., Tembe, W., Ruiz, C. F., Gsponer, J. R., Rentsch, C. A., Bubendorf, L., Stapleton, M., Amorese, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050586 · Cited by 48
Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions
Dinardo, C. D., & Lachowiez, C. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00535-7 · Cited by 49
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Han, S. Y., Mrózek, K., Voutsinas, J. M., Wu, Q. V., Morgan, E. A., Vestergaard, H., Ohgami, R. S., Kluin, P. M., Kristensen, T. K., Pullarkat, S. T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003605 · Cited by 48
Numan, Y., Rahman, Z. A., Grenet, J. E., Boisclair, S., Bewersdorf, J. P., Collins, C. T., Barth, D. M., Fraga, M. S., Bixby, D. L., Zeidan, A. M., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26447 · Cited by 49
Quizartinib for the treatment of acute myeloid leukemia
Garcia‐Horton, A., & Yee, K. W. L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801637 · Cited by 47
Convergent epigenetic evolution drives relapse in acute myeloid leukemia
Nuno, K. A., Azizi, A., Köhnke, T., Lareau, C. A., Ediriwickrema, A., Corces, M. R., Satpathy, A. T., & Majeti, R. (2024) · eLife · doi:10.7554/elife.93019 · Cited by 50
The Role of Symmetric Stem Cell Divisions in Tissue Homeostasis
Yang, J., Plikus, M. V., & Komarova, N. L. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004629 · Cited by 45
Mead, A. J., Neo, W. H., Barkas, N., Matsuoka, S., Giustacchini, A., Facchini, R., Thongjuea, S., Jamieson, L., Booth, C. A. G., Fordham, N., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161418 · Cited by 47
Zebrafish as a model to assess cancer heterogeneity, progression and relapse
Blackburn, J. S., & Langenau, D. M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.015842 · Cited by 52
Bhola, P. D., Mar, B. G., Lindsley, R. C., Ryan, J. A., Hogdal, L. J., Vo, T. T., DeAngelo, D. J., Galinsky, I. A., Ebert, B. L., & Letai, A. G. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82908 · Cited by 46
Changing mutational and adaptive landscapes and the genesis of cancer
Liggett, L. A., & DeGregori, J. V. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.005 · Cited by 48
Parkin, B. L., Londoño-Joshi, A. I., Kang, Q., Tewari, M., Rhim, A. D., & Malek, S. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91964 · Cited by 46
Aasebø, E., Berven, F. S., Hovland, R., Døskeland, S. O., Bruserud, Ø., Selheim, F., & Hernandez-Valladares, M. (2020) · Cancers · doi:10.3390/cancers12061466 · Cited by 46
The Hallmarks of Cancer as Ecologically Driven Phenotypes
Somarelli, J. A. (2021) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2021.661583 · Cited by 46
Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis
Peters, S. L., Hlady, R. A., Opavska, J., Klinkebiel, D. L., Pirruccello, S. J., Talmon, G. A., Sharp, J. G., Wu, L., Jaenisch, R., Simpson, M. A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.364 · Cited by 45
Engle, E. K., Fisher, D. A. C., Miller, C. A., McLellan, M. D., Fulton, R. S., Moore, D. M., Wilson, R. K., Ley, T. J., & Oh, S. T. (2014) · Leukemia · doi:10.1038/leu.2014.289 · Cited by 45
Cancer heterogeneity: origins and implications for genetic association studies
Urbach, D., Lupien, M., Karagas, M. R., & Moore, J. H. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.07.001 · Cited by 44
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution
Sutton, L., & Rosenquist, R. (2014) · Haematologica · doi:10.3324/haematol.2014.115923 · Cited by 45
Ferrell, P. B., Diggins, K. E., Polikowsky, H. G., Mohan, S. R., Seegmiller, A. C., & Irish, J. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153207 · Cited by 46
Melchardt, T., Hufnagl, C., Weinstock, D. M., Kopp, N., Neureiter, D., Tränkenschuh, W., Hackl, H., Weiß, L., Rinnerthaler, G., Hartmann, T. N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9860 · Cited by 52
Piddock, R. E., Bowles, K. M., & Rushworth, S. A. (2017) · Cancers · doi:10.3390/cancers9040029 · Cited by 47
Enhancer dysfunction in leukemia
Bhagwat, A. S., Lu, B., & Vakoc, C. R. (2018) · Blood · doi:10.1182/blood-2017-11-737379 · Cited by 45
Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
Aasebø, E., Berven, F. S., Bartaula-Brevik, S., Stokowy, T., Hovland, R., Vaudel, M., Døskeland, S. O., McCormack, E., Batth, T. S., Olsen, J. V., et al. (2020) · Cancers · doi:10.3390/cancers12030709 · Cited by 44
Long, L., Assaraf, Y. G., Lei, Z., Peng, H., Yang, L., Chen, Z., & Ren, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100703 · Cited by 47
Boutros, P. C., Ewing, A. D., Ellrott, K., Norman, T., Dang, K. K., Hu, Y., Kellen, M., Suver, C., Bare, J. C., Stein, L. D., et al. (2014) · Nature Genetics · doi:10.1038/ng.2932 · Cited by 44
Forristal, C. E., Brown, A. L., Helwani, F., Winkler, I. G., Nowlan, B., Barbier, V., Powell, J. A., Engler, G. A., Diakiw, S. M., Zannettino, A. C. W., et al. (2015) · Leukemia · doi:10.1038/leu.2015.102 · Cited by 49
Mead, A. J., Kharazi, S., Atkinson, D., Macaulay, I. C., Pecquet, C., Loughran, S. J., Lutteropp, M., Woll, P. S., Chowdhury, O., Luc, S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.031 · Cited by 44
Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution
Murugaesu, N., Chew, S. K., & Swanton, C. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.026 · Cited by 42
Bias from removing read duplication in ultra-deep sequencing experiments
Zhou, W., Chen, T., Zhao, H., Eterovic, A. K., Meric‐Bernstam, F., Mills, G. B., & Chen, K. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt771 · Cited by 44
Tomuleasa, C., Petrushev, B., Boca, S., Nagy-Simon, T., Berce, C., Frinc, I., Dima, D. M., Selicean, S. E., Gafencu, G., Tănase, A., et al. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s94064 · Cited by 45
Clonal Analysis of Cells with Cellular Barcoding: When Numbers and Sizes Matter
Bystrykh, L. V., & Belderbos, M. E. (2016) · Methods in molecular biology · doi:10.1007/7651_2016_343 · Cited by 43
Natural and chemotherapy-induced clonal evolution of tumors
Ibragimova, M. K., Tsyganov, M. M., & Литвяков, Н. В. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917040022 · Cited by 44
Beyond molecular tumor heterogeneity: protein synthesis takes control
y Cajal, S. R., Castellví, J., Hümmer, S., Peg, V., Pelletier, J., & Sonenberg, N. (2018) · Oncogene · doi:10.1038/s41388-018-0152-0 · Cited by 44
Bruno, S., Mancini, M., Santis, S. D., Monaldi, C., Cavo, M., & Soverini, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136857 · Cited by 43
Peroni, E., Randi, M. L., Rosato, A., & Cagnin, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02841-8 · Cited by 51
Liu, B., Conroy, J. M., Morrison, C. D., Odunsi, A., Qin, M., Wei, L., Trump, D. L., Johnson, C. S., Liu, S., & Wang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3491 · Cited by 45
Ancient hot and cold genes and chemotherapy resistance emergence
Wu, A. Y., Zhang, Q., Lambert, G., Khin, Z. P., Gatenby, R. A., Kim, H. J., Pourmand, N., Bussey, K. J., Davies, P. C. W., Sturm, J. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512396112 · Cited by 43
Jackson, J. M., Taylor, J. B., Witek, M. A., Hunsucker, S. A., Waugh, J. P., Fedoriw, Y. D., Shea, T. C., Soper, S. A., & Armistead, P. M. (2015) · The Analyst · doi:10.1039/c5an01836f · Cited by 43
Applying next-generation sequencing to pancreatic cancer treatment
Mardis, E. R. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.126 · Cited by 43
Modeling Tumor Clonal Evolution for Drug Combinations Design
Zhao, B., Hemann, M. T., & Lauffenburger, D. A. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.001 · Cited by 42
The Future of Targeting FLT3 Activation in AML
Leick, M. B., & Levis, M. J. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0381-2 · Cited by 43
Jiménez, C., Alonso, S., Alcoceba, M., Ordóñez, G. R., García‐Álvarez, M., Prieto-Conde, I., Chillón, C., Balanzategui, A., Corral, R., Marı́n, L., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.72 · Cited by 44
Effects of thymic selection on T cell recognition of foreign and tumor antigenic peptides
George, J. T., Kessler, D. A., & Levine, H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708573114 · Cited by 41
CD97 is a critical regulator of acute myeloid leukemia stem cell function
Martin, G. H., Roy, N., Chakraborty, S., Desrichard, A., Chung, S. S., Woolthuis, C. M., Hu, W., Berezniuk, I., Garrett-Bakelman, F. E., Hamann, J., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190598 · Cited by 47
A generic, cost-effective, and scalable cell lineage analysis platformPreprint
Biezuner, T., Spiro, A., Raz, O., Amir, S., Milo, L., Adar, R., Chapal-Ilani, N., Berman, V., Fried, Y., Ainbinder, E., et al. (2016) · Genome Research · doi:10.1101/gr.202903.115 · Cited by 41
Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 46
An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape
Bystrom, R. P., & Levis, M. J. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01389-2 · Cited by 43
Leppä, A., Grimes, K., Jeong, H., Huang, F. Y., Andrades, Á., Waclawiczek, A., Boch, T., Jauch, A. S., Renders, S., Stelmach, P., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01999-x · Cited by 43
Lou, Y., Ma, Y., Sun, J., Ye, X., Pan, H., Wang, Y., Qian, W., Meng, H., Mai, W., He, J., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2477-x · Cited by 41
Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas
Ouyang, L., Lee, J., Park, C.-K., Mao, M., Shi, Y., Gong, Z., Zheng, H., Li, Y., Zhao, Y., Wang, G., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-2 · Cited by 42
The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture
Salomoni, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00152 · Cited by 46
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications
de Bruin, E. C., Taylor, T., & Swanton, C. (2013) · Genome Medicine · doi:10.1186/gm505 · Cited by 44
Genomics of Acute Myeloid Leukemia: The Next Generation
Riva, L., Luzi, L., & Pelicci, P. G. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00040 · Cited by 42
Suitability of Different Mapping Algorithms for Genome-Wide Polymorphism Scans with Pool-Seq Data
Kofler, R., Langmüller, A. M., Nouhaud, P., Otte, K. A., & Schlötterer, C. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.116.034488 · Cited by 41
Misyura, M., Zhang, T., Sukhai, M. A., Thomas, M., Garg, S., Kamel‐Reid, S., & Stockley, T. L. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.06.004 · Cited by 42
Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia
Tabe, Y., Tafuri, A., Sekihara, K., Yang, H., & Konopleva, M. Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1333600 · Cited by 44
Methods of Detection of Measurable Residual Disease in AML
Zhou, Y., & Wood, B. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0419-5 · Cited by 41
Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
Panuzzo, C., Signorino, E., Calabrese, C., Ali, M. S., Petiti, J., Bracco, E., & Cilloni, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030802 · Cited by 43
Liu, P., Ma, D., Wang, P., Pan, C., Fang, Q., & Wang, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03331-x · Cited by 43
Turati, V. A., Guerra‐Assunção, J. A., Potter, N. E., Gupta, R., Ecker, S., Daneviciute, A., Tarabichi, M., Webster, A. P., Ding, C., May, G. E., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00219-3 · Cited by 42
Breast Cancer Heterogeneity in Primary and Metastatic Disease
Kalinowski, L., Saunus, J. M., Reed, A. E. M., & Lakhani, S. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_6 · Cited by 47
The prevalent predicament of relapsed acute myeloid leukemia
Szer, J. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.43.3798183 · Cited by 42
HIT’nDRIVE: Multi-driver Gene Prioritization Based on Hitting Time
Shrestha, R., Hodzic, E., Yeung, J., Wang, K., Sauerwald, T., Dao, P., Anderson, S. A., Beltran, H., Rubin, M. A., Collins, C. C., et al. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-05269-4_23 · Cited by 41
Ottone, T., Zaza, S., Divona, M., Hasan, S. K., Lavorgna, S., Laterza, S., Cicconi, L., Panetta, P., Giandomenico, J. D., Cittadini, M., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12288 · Cited by 41
Bleckmann, A., Conradi, L., Menck, K., Schmick, N. A., Schubert, A., Rietkötter, E., Arackal, J., Middel, P., Schambony, A., Liersch, T., et al. (2016) · Clinical and Experimental Metastasis · doi:10.1007/s10585-016-9780-3 · Cited by 38
Lee, J.-M., Kim, Y., Park, S., Han, E., Kim, M., & Kim, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122077 · Cited by 41
Aikawa, T., Togashi, N., Iwanaga, K., OKADA, H. M., Nishiya, Y., Inoue, S., Levis, M. J., & Isoyama, T. (2020) · Oncotarget · doi:10.18632/oncotarget.27489 · Cited by 44
Paolillo, R., Boulanger, M., Gâtel, P., Gabellier, L., de Toledo, M., Tempé, D., Hallal, R., Akl, D., Moreaux, J., Baik, H., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279889 · Cited by 41
McDonald, T. O., Chakrabarti, S., & Franziska Michor, A. (2018) · Nature Genetics · doi:10.1038/s41588-018-0217-6 · Cited by 37
DNA repair and the contribution to chemotherapy resistance
Nesic, K., Parker, P., Swisher, E. M., & Krais, J. J. (2025) · Genome Medicine · doi:10.1186/s13073-025-01488-8 · Cited by 57
Grunwald, M. R., & Levis, M. J. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.004 · Cited by 42
A simple consensus approach improves somatic mutation prediction accuracy
Goode, D. L., Hunter, S. M., Doyle, M., Ma, T., Rowley, S. M., Choong, D., Ryland, G. L., & Campbell, I. (2013) · Genome Medicine · doi:10.1186/gm494 · Cited by 40
Cha, S., Lee, J., Shin, J.-Y., Kim, J. Y., Sim, S. H., Keam, B., Kim, T. M., Kim, D.-W., Heo, D. S., Lee, S.-H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2209-1 · Cited by 40
High-grade serous ovarian cancer: the clone wars
Salomon‐Perzyński, A., Salomon-Perzyńska, M., Michalski, B., & Skrzypulec‐Plinta, V. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4292-1 · Cited by 43
FLT3 inhibitors: clinical potential in acute myeloid leukemia
Hospital, M., Green, A. S., Maciel, T. T., Moura, I. C., Leung, A. Y. H., Bouscary, D., & Tamburini, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s103790 · Cited by 39
Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia
Ricciardi, M. R., Mirabilii, S., Licchetta, R., Piedimonte, M., & Tafuri, A. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.002 · Cited by 41
Caiado, F., Maia-Silva, D., Jardim, C., Schmolka, N., Carvalho, T., Reforço, C., Faria, R., Kolundžija, B., Simões, A. E. S., Baubec, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12983-z · Cited by 41
Marçais, A., Lhermitte, L., Artesi, M., Laurent, C., Durkin, K., Hahaut, V., Rosewick, N., Suárez, F., Sibon, D., Cheminant, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0900-3 · Cited by 47
Short, N. J., Rafei, H., Daver, N. G., Hwang, H., Ning, J., Jorgensen, J. L., Kadia, T. M., Dinardo, C. D., Wang, S. A., Jabbour, E. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002811 · Cited by 41
Zeidan, A. M., Giagounidis, A. A. N., Sekeres, M. A., Xiao, Z., Sanz, G. F., Hoef, M. V., Ma, F., Hertle, S., & Santini, V. (2023) · Future Oncology · doi:10.2217/fon-2022-1237 · Cited by 41
Zhai, Y., Singh, P., Dolnik, A., Brázda, P., Atlasy, N., Gaudio, N. D., Döhner, K., Döhner, H., Minucci, S., Martens, J. H. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01635-4 · Cited by 38
Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia
Bochtler, T., Fröhling, S., & Krämer, A. (2015) · Leukemia · doi:10.1038/leu.2015.32 · Cited by 39
Gellert, P., Segal, C. V., Gao, Q., López‐Knowles, E., Martin, L., Dodson, A. R., Li, T., Miller, C. A., Lu, C., Mardis, E. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13294 · Cited by 39
New insights into the earliest stages of colorectal tumorigenesis
Sievers, C. K., Grady, W. M., Halberg, R. B., & Pickhardt, P. J. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1330150 · Cited by 40
Modeling the Subclonal Evolution of Cancer Cell Populations
Chowell, D., Napier, J., Gupta, R. V., Anderson, K. S., Maley, C. C., & Sayres, M. A. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1229 · Cited by 40
Roh, V., Abramowski, P., Hiou‐Feige, A., Cornils, K., Rivals, J. P., Zougman, A., Aranyossy, T., Thielecke, L., Truan, Z., Mermod, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.090 · Cited by 38
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
O’Donnell, T. J., Christie, E. L., Ahuja, A., Buros, J. L., Aksoy, B. A., Bowtell, D. D. L., Snyder, A., & Hammerbacher, J. (2018) · BMC Cancer · doi:10.1186/s12885-017-3825-0 · Cited by 40
Stiehl, T., Wang, W., Lutz, C., & Marciniak-Czochra, A. K. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0283 · Cited by 39
Evolving insights: how DNA repair pathways impact cancer evolution
Zhou, J., Zhou, X. A., Zhang, N., & Wang, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0177 · Cited by 40
Metadata
- Authors
- Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Ley, Timothy J.
- ORCID
- Ding, Li
- Ley, Timothy J.
- Larson, David E.
- Miller, Christopher A.
- Koboldt, Daniel C.
- Welch, John S.
- Ritchey, Julie K.
- McLellan, Michael D.
- McMichael, Joshua F.
- Lu, Charles
- Shen, Dong
- Fulton, Robert S.
- Fulton, Lucinda L.
- Chen, Ken
- Magrini, Vincent J.
- McGrath, Sean D.
- Vickery, Tammi L.
- Wendl, Michael C.
- Heath, Sharon
- Watson, Mark A.
- Link, Daniel C.
- Tomasson, Michael H.
- Payton, Jacqueline E.
- Kulkarni, Shashikant
- Walter, Matthew J.
- Graubert, Timothy A.
- Mardis, Elaine R.
- Wilson, Richard K.
- DiPersio, John F.
- Venue
- Nature
- Published
- 2012-01
- Volume
- 481
- Issue
- 7382
- Pages
- 506-510
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3267864
- OpenAlex
- W2093144236
- Cited by
- 1,993
- References
- 30
- Citations by year
- 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
- FWCI
- 149.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Foundation for Barnes-Jewish Hospital (00335-0505-02)
- National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
- National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
- MeSH terms
- Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
